Notable Labs
Notable Labs
NTBL
NASDAQ
0.57
USD
2,750.00%
About
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments.
The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 36.6K |
| Three Month Average Volume | 1.9M |
| High Low | |
| Fifty-Two Week High | 10.08 USD |
| Fifty-Two Week Low | 0.452 USD |
| Fifty-Two Week High Date | 12 Oct 2023 |
| Fifty-Two Week Low Date | 06 Aug 2024 |
| Price and Volume | |
| Current Price | 0.5696 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.88% |
| Thirteen Week Relative Price Change | -46.78% |
| Twenty-Six Week Relative Price Change | -63.52% |
| Fifty-Two Week Relative Price Change | -94.07% |
| Year-to-Date Relative Price Change | -74.55% |
| Price Change | |
| One Day Price Change | -7.37% |
| Thirteen Week Price Change | -43.04% |
| Twenty-Six Week Price Change | -59.89% |
| Five Day Price Change | -5.22% |
| Fifty-Two Week Price Change | -92.57% |
| Year-to-Date Price Change | -69.86% |
| Month-to-Date Price Change | -0.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.67593 USD |
| Book Value Per Share (Most Recent Quarter) | 0.74393 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.67593 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.74393 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.91333 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.09386 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.04599 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.41042 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.4729 USD |
| Normalized (Last Fiscal Year) | -3.41042 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.41042 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.4729 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.41042 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.4729 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.31123 USD |
| Cash Per Share (Most Recent Quarter) | 0.42362 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.31232 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.39685 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.50044 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -3,392 |
| Cash Flow Revenue (Trailing Twelve Months) | -5,437 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -5,346.97% |
| Pretax Margin (Last Fiscal Year) | -3,633.55% |
| Pretax Margin (5 Year) | -3,636.93% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 36.45% |
| Gross Margin (Trailing Twelve Months) | 37.70% |
| Gross Margin (5 Year) | 60.19% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -4,728.06% |
| Operating Margin (Trailing Twelve Months) | -6,493.61% |
| Operating Margin (5 Year) | -3,791.03% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3,633.55% |
| Net Profit Margin (Trailing Twelve Months) | -5,346.97% |
| Net Profit Margin (5 Year) | -3,636.93% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -49.65% |
| Tangible Book Value (5 Year) | -22.22% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -11.93% |
| Revenue Change (Trailing Twelve Months) | -34.93% |
| Revenue Per Share Growth | -31.47% |
| Revenue Growth (5 Year) | -30.46% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -50.69% |
| Total Debt (5 Year) | -15.59% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -41.45% |
| EPS Change (Trailing Twelve Months) | 65.58% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -3,789,000 |
| Net Debt (Last Fiscal Year) | -11,484,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 18 |
| Price to Sales (Trailing Twelve Months) | 18 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 2 |
| Long Term Debt to Equity (Most Recent Quarter) | 3 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -13,781,000 |
| Free Cash Flow (Trailing Twelve Months) | -17,017,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 2 |
| Total Debt to Equity (Most Recent Quarter) | 4 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.79% |
| Return on Assets (Trailing Twelve Months) | -93.89% |
| Return on Assets (5 Year) | -52.02% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -59.97% |
| Return on Equity (Trailing Twelve Months) | -126.68% |
| Return on Equity (5 Year) | -66.66% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -56.70% |
| Return on Investment (Trailing Twelve Months) | -120.26% |
| Return on Investment (5 Year) | -62.09% |